Journals / Türk Patoloji Dergisi / 2020 / Cilt: 36 - Sayı: 1

Relation Between Immunohistochemical Expression of Hippo Pathway Effectors and Chronic Hepatitis Induced Fibrosis in Egyptian Patients

Pages
48–63
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

YAP and TAZ expression were correlated with severity of hepatocyte injury togetherwith fibrosis in chronic viral cases but these correlations were absent in AIH cases despite the pronounced increase of YAP and TAZ nuclearlocalization.Conclusion: The correlation between Hippo effectors activation and fibrosis in chronic viral hepatitis patients emphasize their role in thedevelopment and advancement of hepatic scarring and highlight the use of both YAP and TAZ as novel targets to ameliorate liver fibrosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Chronic hepatitis is a global health problem especially in Egypt.
📊
Key Findings & Data:Recently, a few studies have linked Hippo pathway effectors of yes-associated protein (YAP) and its paralog transcriptionalcoactivator with PDZ-binding motif (TAZ) to extracellular matrix deposition and ongoing fibrosis.Material and Method: Immunohistochemical expression of YAP and TAZ were analyzed in 121 liver needle core biopsies (91 core biopsies ofchronic viral hepatitis, 20 biopsies of autoimmune hepatitis and 10 normal liver cores).Results: YAP and TAZ nuclear localization was absent in all normal liver cores.
💡
Conclusion & Impact:YAP and TAZ expression were correlated with severity of hepatocyte injury togetherwith fibrosis in chronic viral cases but these correlations were absent in AIH cases despite the pronounced increase of YAP and TAZ nuclearlocalization.Conclusion: The correlation between Hippo effectors activation and fibrosis in chronic viral hepatitis patients emphasize their role in thedevelopment and advancement of hepatic scarring and highlight the use of both YAP and TAZ as novel targets to ameliorate liver fibrosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Chronic hepatitis is a global health problem especially in Egypt. Hepatic fibrosis is a common end clinical manifestation of manychronic liver diseases. Although it is a wound-healing process, excessive accumulation of fibrillary collagen leads to architectural damage, cirrhosisand liver failure. Recently, a few studies have linked Hippo pathway effectors of yes-associated protein (YAP) and its paralog transcriptionalcoactivator with PDZ-binding motif (TAZ) to extracellular matrix deposition and ongoing fibrosis.Material and Method: Immunohistochemical expression of YAP and TAZ were analyzed in 121 liver needle core biopsies (91 core biopsies ofchronic viral hepatitis, 20 biopsies of autoimmune hepatitis and 10 normal liver cores).Results: YAP and TAZ nuclear localization was absent in all normal liver cores. Autoimmune hepatitis cases showed higher nuclear expressionof both YAP and TAZ in comparison to chronic viral cases. YAP and TAZ expression were correlated with severity of hepatocyte injury togetherwith fibrosis in chronic viral cases but these correlations were absent in AIH cases despite the pronounced increase of YAP and TAZ nuclearlocalization.Conclusion: The correlation between Hippo effectors activation and fibrosis in chronic viral hepatitis patients emphasize their role in thedevelopment and advancement of hepatic scarring and highlight the use of both YAP and TAZ as novel targets to ameliorate liver fibrosis.

🔖

Cite This Article

ABDALLAH, R. A., SHABAN, M. I., TAIE, D. M., ASAAD, N. Y., BADR, A. H. A. E. B. (2022). Relation Between Immunohistochemical Expression of Hippo Pathway Effectors and Chronic Hepatitis Induced Fibrosis in Egyptian Patients. Türk Patoloji Dergisi, Cilt: 36 - Sayı: 1, 48–63. https://ajindex.com/articles/640400

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology. 1994;19:1513-20
  2. McMahon B, Townshend-Bulson L, Gounder P, Bruce M, Simmons B. New Prospects for Hepatitis C treatment and new WHO Guidelines for the management of Hepatitis B and C. Abstracts from the 16th International Congress on Circumpolar Health. Int J Circumpolar Health. 2016 Jan;75(1):33200
  3. Ismail SA, Cuadros DF, Benova L. Hepatitis B in Egypt: A cross-sectional analysis of prevalence and risk factors for active infection from a nationwide survey. Liver Int. 2017;37:1814-22
  4. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22:7824-40
  5. Kandeel A, Genedy M, El‐Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: Implications for future policy on prevention and treatment. Liver Int. 2017;37:45-53
  6. Gomaa A, Allam N, Elsharkawy A, El Kassas M, Waked I. Hepatitis C infection in Egypt: Prevalence, impact and management strategies. Hepat Med. 2017;9:17-25
  7. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546-55
  8. Jepsen P, Grønbæk L, Vilstrup H. Worldwide incidence of autoimmune liver disease. Dig Dis. 2015;33:2-12
  9. Ngu JH, Gearry RB, Frampton CM, Stedman CA. Predictors of poor outcome in patients with autoimmune hepatitis: A population‐based study. Hepatology. 2013;57:2399-406
  10. Mitra A, Satelli A, Yan J, Xueqing X, Gagea M, Hunter CA, Mishra L, Li S. IL‐30 (IL27p28) attenuates liver fibrosis through inducing NKG2D‐rae1 interaction between NKT and activated hepatic stellate cells in mice. Hepatology. 2014;60:2027-39
  11. Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int. 2013;33:93-104
  12. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: Nearing the starting line. Sci Transl Med. 2013;5:167sr1
  13. Zheng X-Y, Zhao X, Yang Y-F, Jiang H-J, Li W, Sun Y, Pu X-P. Antioxidant, antiapoptotic and amino acid balance regulating activities of 1, 7-dihydroxy-3, 4, 8-trimethoxyxanthone against dimethylnitrosamine-induced liver fibrosis. PloS